@entity263 after external radiotherapy. Role of XXXX and transrectal ultrasonography.

@entity1 @entity263 @entity5 @entity1486
BACKGROUND: Although the incidence of positive post-radiotherapy biopsies has been reported, the range is considerable (19-93%) and depends partly on @entity1 -selection criteria. In addition, the prognostic significance of transrectal ultrasonography (TRUS) and @entity1486 (PSA) used alone and in combination in predicting @entity5 after radiotherapy has yet to be determined. METHODS: Transrectal ultrasonography-guided prostate biopsies were performed on 31 unselected @entity1 with @entity263 34-77 months (mean, 51 months) after definitive external beam radiotherapy was completed. Biopsy results were compared for pre- and posttreatment parameters (clinical stage, grade, PSA, and TRUS). RESULTS: In 22 @entity1 (71%), @entity5 was detected histologically by biopsy. All but one @entity1 (12/13, 92%) with a pretherapy PSA value greater than 10 ng/mL had a positive biopsy compared with 50% of those (7/14) with a pretherapy PSA value less than or equal to 10 (P < 0.05). After radiotherapy, a positive biopsy was noted for 15 of 16 @entity1 (94%) with a PSA value greater than 2 and in 20 of 23 (87%) of those with abnormal TRUS findings (P < 0.01 and P < 0.005, respectively). CONCLUSIONS: The most clinically useful model for predicting histologically identifiable @entity5 was either a serum PSA value greater than 2 or a PSA value less than or equal to 2 and abnormal TRUS findings. The positive and negative predictive values of the model were 84% and 83%, respectively. The model predicted biopsy results correctly in 26 of 31 @entity1 (84%). Transrectal ultrasonography is recommended as a diagnostic tool for @entity1 whose PSA level ranges from a detectable level to less than or equal to 2 ng/mL.
